Hero Image

5 New Weight Loss Injections in 2025 (You Won’t Believe #5)

In 2025, prescription weight loss injections continue to dominate the obesity treatment space—and the newest options are more powerful, precise, and personalized than ever before. If you’re looking for what’s next in the world of medically assisted weight loss, these new injections could change everything.

From next-generation GLP-1 agonists to completely new metabolic targets, here are five of the most talked-about weight loss injections this year—with #5 offering a surprising twist few saw coming.

1. Zepbound (tirzepatide)

After its FDA approval in late 2023, Zepbound became the fastest-growing weight loss injection in 2024—and it’s still dominating in 2025. This dual-action medication targets both GLP-1 and GIP receptors, giving it a double mechanism of appetite and metabolism control.

Studies have shown patients losing up to 22% of body weight, outperforming previous medications like Wegovy. Zepbound is taken weekly and is now widely available with improved insurance coverage in most states.

2. Retatrutide (LY3437943)

Expected to gain full FDA approval by mid-2025, Retatrutide is the first triple-action weight loss injection—targeting GLP-1, GIP, and glucagon receptors simultaneously.

Early clinical trials from Eli Lilly showed jaw-dropping results: average weight loss over 24%, with some participants shedding nearly a third of their body weight. Retatrutide is expected to become a go-to for patients who’ve hit plateaus on other injectables.

3. CagriSema

A combination of semaglutide and cagrilintide, CagriSema has gained fast attention in 2025 for being one of the most potent GLP-1 combos yet. While semaglutide (found in Wegovy) reduces appetite, cagrilintide amplifies satiety signals and delays gastric emptying.

Together, they form a one-two punch that helps users eat less and feel full longer. It’s taken weekly, and early adopters report strong results with fewer side effects than high-dose semaglutide alone.

4. Amylin Analog AMX0035 (under review)

Still in the final phases of FDA review, AMX0035 is an amylin analog, a different class of hormone that regulates blood sugar and delays gastric emptying. While not a GLP-1, this injectable has shown promising early data, especially when combined with lifestyle coaching.

Unlike other injectables, it may be particularly effective in patients with insulin resistance or borderline diabetes who haven’t responded to GLP-1 therapies.

**5. Epiglutide: The Brain-Boosting Weight Loss Injection

Here’s the curveball: Epiglutide, a new investigational compound, is turning heads in 2025 not just for its weight loss properties—but for its surprising impact on mood, focus, and cognitive clarity.

Still in early-stage trials, Epiglutide targets a slightly modified GLP-1 receptor pathway with enhanced brain permeability. Test groups have reported not only steady fat loss, but also improved concentration, motivation, and decreased emotional eating.

If approved, Epiglutide could launch a new generation of “mind-body” injectables that help tackle the psychological and behavioral side of weight gain—not just appetite.

Where to Find These Injections

Interested in exploring these new options? Some are already available by prescription, while others may be accessible through clinical trial enrollment or early access programs:

  • Zepbound – Now available at most major pharmacies and weight loss clinics.
  • Retatrutide Trials – Enrollment and updates via Eli Lilly.
  • CagriSema Info – Access via participating endocrinologists.
  • AMX0035 Trials – Check for local clinical trials in your region.
  • Weight Loss Clinics with Experimental Options – Providers like Ro and Found may offer early screening or off-label insights.

Final Thoughts

If you’ve been waiting for better, faster, or more tolerable options in the world of weight loss injections, 2025 delivers. With breakthroughs like Retatrutide and CagriSema already making waves—and surprising newcomers like Epiglutide on the horizon—patients now have more choices than ever.

These injections aren’t shortcuts. But for those medically eligible, they offer powerful support in reclaiming both health and confidence. The future of weight loss is here—and it’s injected.

Sources

Zepbound – https://www.zepbound.com

Eli Lilly – https://www.lilly.com/news/retatrutide-clinical-trials

Novo Nordisk – https://www.novonordisk.com/news-and-media/news.html

ClinicalTrials.gov – https://www.clinicaltrials.gov

Ro Health – https://www.ro.co/weight-loss